Omeros corporation news8/8/2023 Food and Drug Administration (FDA) of its rolling Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA or TA-TMA). Omeros will complete submission next week to the U.S. This includes $93.7 million in proceeds from a common stock offering and $76.9 million in proceeds from the issuance of convertible notes, following the use of a portion of the proceeds to repurchase a portion of our previously outstanding convertible notes and enter into certain derivative transactions, all of which took place during the third quarter. Net loss and adjusted net loss include the $8.7 million deduction in third quarter 2020 revenues for the return reserve.Īt September 30, 2020, the company had cash, cash equivalents and short-term investments available for operations of $153.5 million. On a non-GAAP basis, adjusted net loss for the third quarter of 2020 was $19.9 million, or $0.34 per share, after excluding non-cash expenses and a $5.0 million technology access fee. This compares to a net loss of $16.5 million, or $0.33 per share, in the third quarter of 2019. Net loss in the third quarter of 2020 was $38.5 million, or $0.66 per share, of which $13.6 million, or $0.23 per share, were non-cash expenses. For comparison, third quarter 2019 and second quarter 2020 revenues were $29.9 million and $13.5 million, respectively. Omeros believes that it qualifies for and is pursuing separate payment from the Centers for Medicare and Medicaid Services (CMS) for OMIDRIA. Revenues for the third quarter of 2020 were $26.1 million following an $8.7 million deduction as a return reserve associated with the expiration of pass-through reimbursement for OMIDRIA on October 1, 2020. Numerous restaurant employees used the priest’s services when Hernandez offered them, according to an investigator with the Wage and Hour Department.Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2020, which include: “This employer’s despicable attempts to retaliate against employees were intended to silence workers, obstruct an investigation and prevent the recovery of unpaid wages.” “Under oath, an employee of Taqueria Garibaldi explained how the restaurant offered a supposed priest to hear their workplace ‘sins’ while other employees reported that a manager falsely claimed that immigration issues would be raised by the department’s investigation,” said Marc Pilotin, the regional solicitor of labor. The restaurant’s operators - Eduardo Hernandez, Hector Manual Martinez Galindo and Alejandro Rodriguez - were ordered in May by a federal judge in the Eastern District of California to pay $140,000 in back pay and damages to restaurant employees as part of a settlement in the case. The owners of the restaurant were also accused by the department of interfering with the investigation and threatening employees with adverse immigration consequences if they participated in the investigation. Taqueria Garibaldi was under investigation at the time by the Wage and Hour Department for allegedly withholding tips from its employees and for failing to pay them the required time and a half for overtime hours worked.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |